Fast, Easy Nasal Swab Helps Diagnose Asthma Type in Kids

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 2, 2025.

By Dennis Thompson HealthDay Reporter

THURSDAY, Jan. 2, 2024 -- Not sure what’s causing your child’s asthma?

A new quick-and-easy nasal swab test for kids can diagnose the specific immune system drivers behind their asthma, potentially opening the door to better treatments, researchers say.

The test diagnoses a child’s asthma subtype, also called an endotype.

“Because asthma is a highly variable disease with different endotypes, which are driven by different immune cells and respond differently to treatments, the first step toward better therapies is accurate diagnosis of endotype,” senior researcher Dr. Juan Celedon, chief of pulmonary medicine at the UPMC Children’s Hospital of Pittsburgh, said in a news release from the hospital.

Asthma is the most common chronic disease of childhood, affecting about 1 in every 10 kids, according to the National Institutes of Health.

Traditionally, doctors classify asthma into different subtypes based on the immune cells that are causing inflammation that chokes off airways. There’s T2-high driven by T helper 2 cells, T17-high driven by T helper 17 cells, and low-low in which neither type of cell appears to be the cause.

Precisely diagnosing an asthma subtype involves putting a kid under anesthesia and taking a small sample of lung tissue, which is then subjected to genetic analysis, researchers said.

That procedure is so invasive that it’s just not worth it for kids with milder asthma, so doctors instead must guess asthma subtype based on tests of blood, lung function and other allergies, Celedon explained.

“These tests allow us to presume whether a child has T2-high disease or not,” Celedón said. “But they are not 100% accurate, and they cannot tell us whether a child has T17-high or low-low disease. There is no clinical marker for these two subtypes. This gap motivated us to develop better approaches to improve the accuracy of asthma endotype diagnosis.”

For the new study published Jan. 2 in the Journal of the American Medical Association, the researchers collected nasal samples from nearly 460 kids and analyzed them for the presence of eight genes linked to T2 or T17 immune cells.

The samples were drawn from three independent U.S. studies that focused on Puerto Rican and African American children, who have higher rates of asthma and are more likely to die from the disease, researchers said.

The nasal swab analysis accurately revealed the specific subtype of each child’s asthma, results show.

The new test specifically can help steer kids with T2-high asthma to powerful new drugs which target the immune cells that drive the disease, researchers said. As many as 29% of the children had T2-high asthma.

No such treatments yet exist for the other two major subtypes of asthma, Celedon said.

“We have better treatments for T2-high disease, in part, because better markers have propelled research on this endotype,” Celedon said. “But now that we have a simple nasal swab test to detect other endotypes, we can start to move the needle on developing biologics for T17-high and low-low disease.”

The rapid test also could aid other areas of asthma research.

“One of the million-dollar questions in asthma is why some kids get worse as they enter puberty, some stay the same and others get better,” Celedon continued. “Before puberty, asthma is more common in boys, but the incidence of asthma goes up in females in adulthood.”

“Is this related to endotype? Does endotype change over time or in response to treatments? We don’t know. But now that we can easily measure endotype, we can start to answer these questions,” Celedon concluded.

Sources

  • University of Pittsburgh, news release, Jan. 2, 2024

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2025-01-03 06:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords